Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gardasil 9 + menveo
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
Gardasil 9 + MenVeo is a combination of two vaccines administered concomitantly to provide protection against both human papillomavirus (HPV) and invasive disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135. Gardasil 9 is a recombinant vaccine that targets nine HPV types (6, 11, 16, 18, 31, 33, 45, 52, and 58), preventing cervical cancer and other HPV-related diseases by inducing neutralizing antibodies against the L1 protein of these HPV types. MenVeo is a quadrivalent conjugate vaccine containing oligosaccharides from Neisseria meningitidis serogroups A/C/Y/W-135 conjugated to the CRM197 protein; it works by inducing bactericidal antibodies against these serogroups. Both vaccines are indicated for use in adolescents and young adults. Clinical studies have shown that coadministration does not interfere with immunogenicity or safety profiles of either vaccine[2][5][7].
- Brand names
- Menveo + Gardasil 9
- Other names
- human papillomavirus 9-valent vaccine recombinant + meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine
02
Targets
NeuraminidaseHPV L1 (Human papillomavirus L1 capsid protein)
Beyond the preview
Go deeper on gardasil 9 + menveo.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gardasil 9 + menveo.